Advances in molecular mechanisms and immunotherapy involving the immune cell-promoted epithelial-to-mesenchymal transition in lung cancer

Serena De Matteis, Matteo Canale, Alberto Verlicchi, Giuseppe Bronte, Angelo Delmonte, Lucio Crinò, Giovanni Martinelli, Paola Ulivi

Research output: Contribution to journalReview articlepeer-review

Abstract

Immunotherapy has offered a new opportunity for the treatment of many malignancies. In patients with lung cancer, immune checkpoint inhibitors have significantly improved survival. However, little is known about predictive factors or primary and acquired resistance mechanisms. Epithelial-to-mesenchymal transition (EMT) is a complex of phenotypic changes involved in carcinogenesis and resistance to cancer treatments. Specifically, immune cells in the tumor microenvironment can promote EMT, and mesenchymal phenotype acquisition negatively regulates the anticancer immune response. EMT is associated with higher expression of PD-L1 and other immune checkpoints. In this review, we focused on the role of EMT in the interplay between tumor cells and the immune system, with particular emphasis on lung cancer. On the basis of our findings, we hypothesize that the effects of EMT on immune cells could be overcome in this disease by a new combination of immune checkpoint inhibitors.

Original languageEnglish
Article number7475364
JournalJournal of Oncology
Volume2019
DOIs
Publication statusPublished - Jan 1 2019

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Advances in molecular mechanisms and immunotherapy involving the immune cell-promoted epithelial-to-mesenchymal transition in lung cancer'. Together they form a unique fingerprint.

Cite this